Kornimate/medical-research-clean huggingface dataset:
an efficacy and safety study of cisapride in patients with chronic gastroparesis after failure of other treatment options

Conditions: Gastroparesis

Summary: the purpose of this study is to assess the effectiveness of cisapride in patients with a primary diagnosis of chronic gastroparesis (a stomach disorder) of unknown cause.

this is a double-blind (neither the physician nor the patient will know the name of assigned treatment) study to determine the effectiveness of cisapride tablets compared to placebo tablets (a tablet identical in appearance to cisapride but does not contain active drug) in patients with a primary diagnosis of idiopathic gastroparesis (a disorder of unknown cause in which the stomach empties its contents very slowly into the small intestine for digestion. symptoms of gastroparesis may include vomiting, nausea, early feeling of fullness after only a few bites of food, weight loss due to poor absorption of nutrients or low calorie intake, abdominal bloating, poor glycemic (blood sugar) control, lack of appetite, and pain in the stomach area. patients will take study drug (one 10-mg tablet of cisapride, or one tablet of placebo), orally, 4 times a day, for a period of 8 weeks. study drug will be taken approximately 15 minutes before each meal, and, with a beverage, before going to bed.

Eligibility criteria:
inclusion criteria: * diagnosed with nondiabetic idiopathic gastroparesis and having symptoms for at least 12 weeks in the preceeding 12 months * experienced inadequate response, or intolerance to therapy to date * have exacerbation of gastroparesis symptoms requiring medical attention * demonstrate delayed gastric emptying as assessed by a \[1-13c\]-sodium acetate breath test within 14 days before randomization exclusion criteria: * received prior treatment with cisapride * have a gycosylated hemoglobin (hba1c) \>7% and bloodglucose of 126 mg/dl (7.0 mmol/l) or greater at screening, as determined by clinical laboratory testing * have any upper gastrointestinal (gi) pathology other than idiopathic gastroparesis that would require therapy other than that provided in this trial * have any organic/neurological disease that is suspected to be causing gastroparesis * currently vomiting, or receiving therapy for a severe exacerbation of gastroparesis, that would prevent the patient from receiving oral therapy or a diet

Keywords: cisapride ( prepulsid ) placebo idiopathic stomach diseases stomach
effect of transform burn on weight loss

Conditions: Weight Loss

Summary: this study was undertaken to explore the effects of a thermogenic composition (tc) composed of dihydrocapsiate, red pepper (capsicum annuum) fruit extract, citrus (citrus spp) peel extract, coleus (coleus forskholi) root extract, and african mango (irvingia gabonensis) seed extract to support body composition, weight management, and improve parameters related to energy, hunger, and satiety on healthy adult women and men over a 12-week interval.


Eligibility criteria:
inclusion criteria: * individuals could participate who were at least 18 years old and not smokers. * not currently taking a dietary supplement or prescription for weight loss. * exercising volunteers were asked to maintain their regimen consistently throughout the course of the 12-week study and caffeine drinking volunteers maintained their caffeine intake consistently throughout the course of the 12-week study. exclusion criteria: * participants were not allowed to participate if they were pregnant or planning to become pregnant in the following 12 weeks, or lactating. * individuals were not allowed to participate if they were taking any stimulant medications.
the effects of ramipril on clinical symptoms in patients with peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: one important clinical challenge in older individuals is maintaining mobility in the absence of pain. peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility. conventional therapies have only modest effect in improving symptoms. the investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.


Eligibility criteria:
inclusion criteria: * ankle-brachial index of \<0.9 at rest in at least one leg * history of intermittent claudication (unilateral or bilateral) which was stable for 6 months * evidence of superficial femoral artery stenosis or occlusion on duplex scan * blood pressure \<=160/90 mmhg * stable medication regimen for at least 6 months and not previously treated with ace inhibitors exclusion criteria: * limiting coronary artery disease * renal failure * history of hypertension * history of type 2 diabetes mellitus
study to improve partner services for std prevention

Conditions: Trichomonas Vaginalis; Urethritis

Summary: the goal of this study was to examine the efficacy of patient-delivered partner treatment (pdpt) compared to standard partner referral (pr) and booklet enhanced partner referral (bepr).

for partner treatment, index women who were diagnosed with trichomonas vaginalis and index men who were diagnosed with urethritis were randomized to one of three study arms: standard partner referral (pr) - index patients were instructed to tell their partners that they need to go to a clinic for sti evaluation and treatment. booklet-enhanced partner referral (bepr) - index patients were given a wallet-sized booklet containing 4 tear-out cards with information for the partner and treatment guidelines for the providers that would see the partners. the partners could then present this card at a clinic to help the clinician better treat them. if index patients had more than 4 partners, they were given additional booklets. patient delivered partner treatment (pdpt) - index patients were given packages containing 2 gram metronidazole (for tv patients) or azithromycin 1 gram and cefixime 400 mg (for urethritis patients) for up to 4 identified sex partners. when cefixime was no longer available, ciprofloxacin 500 mg was used. these packages contained written instructions about how to take the medication, warnings about side effects and a nurse's pager number to call if there were any questions or if the partner encountered any problems. all medications were distributed in containers with childproof caps and the partner's initial and birthdates were written on the bottle. this was a requirement of the louisiana state pharmacy board. names were not documented on the index patient's study or medical records.

Eligibility criteria:
inclusion criteria: * woman attending family planning clinic or men attending std clinic * aged 16-44 * (non-pregnant women) - positive inpouch for trichomonas, or * (pregnant women) - positive wet mount or inpouch for trichomonas vaginalis * (men) a complaint of urethritis which is verified on examination * report having \>= 1sex partners in past 60 days * not presumptively treated for trichomonas (women) or urethritis (men) * provide informed consent to be re-contacted by telephone or in person in 14-28 days for a follow-up interview and t vaginalis or ct/gc rescreening exclusion criteria: men * prisoner * has taken cefixime or azithromycin in last two weeks * has previously participated in the study * all female partners are pregnant and did not have male partners women * client has taken metronidazole in the last two weeks * client has been in this study previously * women who are asymptomatic and in their first trimester of pregnancy

Keywords: patient-delivered partner treatment partner referral sexually transmitted diseases
relative bioavailability, pharmacokinetics, safety and tolerability of biil 284 bs in healthy volunteers

Conditions: Healthy

Summary: the objective of the present study is to investigate the relative bioavailability of biil 284 bs boli in comparison to the tablet c at a dose of 75 mg in fasted condition and after a standard breakfast in healthy male volunteers


Eligibility criteria:
inclusion criteria: * all participants are healthy males * age range from 21 to 50 years * broca-index: within +- 20% of normal weight exclusion criteria: * any finding of the medical examination (including blood pressure, pulse rate and ecg) deviating from normal and of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * diseases of the central nervous system (such as epilepsy) or with psychiatric disorders * history of orthostatic hypotension, fainting spells or blackouts * chronic or relevant acute infections * history of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * intake of a drug with a long half-life (\> 24 hours) within one month or less than ten half-lives of the respective drug before enrollment in the study * use of any drugs which might influence the results of the trial (\>= one week prior to administration or during the trial) * participation in another study with an investigational drug (\>= tow months prior to administration or during the trial) * smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day) * inability to refrain from smoking on study days * alcohol abuse (\> 60g/day) * drug abuse * blood donation (\>= 100 ml) within four weeks prior to administration or during the trial * excessive physical activities (within the last week before the study) * any laboratory value outside the reference range of clinical relevance
telemedicine for patients suffering from copd (danish telecare north trial)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: there are two main aims in this study. the first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from copd that may benefit from telehealth compared with only standard treatment and care. the second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with copd across patients and municipality districts. it is hypothesized that telehealth care will increase patients quality adjusted life years at both the cluster and individual level compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. however, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Eligibility criteria:
inclusion criteria: * diagnosed copd by spirometry * in treatment corresponding to gold-guidelines * motivated for treatment of copd * copd is the primary disease * fixed residence and be affiliated to a general practitioner in north denmark region * at least one of the following criteria should also be met: mrcm (modified) ≥ 2 or mrc ≥3, cat ≥ 10, have had at least 2 exacerbations within the last 12 months exclusion criteria: * no phone line or gsm coverage * unable to understand danish sufficiently to complete study questionnaires * have a cognitive impairment
tee 3d rv assessment for savr, mini avr, and tavr

Conditions: Right Ventricular Dysfunction

Summary: three-dimensional echocardiography has become a gold standard to assess right ventricular (rv) function, and investigators plan to use 3d transesophageal echocardiography to assess rv function in 3 types of aortic valve replacement (avr): surgical avr (savr), mini-sternotomy avr (mini avr), and transcatheter avr (tavr).

objective: right ventricular (rv) function is known to be a critical factor to determine postoperative outcome in cardiac surgery, and echocardiography plays an important role in rv function assessment. in the previous studies, rv function was reported to be more reduced in surgical aortic valve replacement (savr) than transcatheter aortic valve replacement (tavr), but its assessment was performed by 2-dimensional echocardiography. on the other hand, three-dimensional (3d) echocardiography has been the gold standard to assess rv systolic function (ef: ejection fraction), and its intraoperative use is getting more useful in cardiac surgery given recent technological advance in echocardiography machines. however, realty is that rv function assessment is based on subjective information or traditional rv function indices, mostly due to unfamiliarity of 3d technique. in this study, the investigators plan to evaluate intraoperative rv function assessment by 3d transesophageal echocardiography (tee). the investigators will compare 3d rv ef with other traditional rv function indices (rv size, right ventricular index of myocardial performance (rimp), rv fractional area change (fac), peak systolic velocity of the lateral tricuspid annulus (s'), tricuspid annular plane systolic excursion (tapse), speckle tracking echocardiography (ste) in savr, mini-sternotomy avr (mini avr), and tavr.

Eligibility criteria:
inclusion criteria: * adult patients over 18 years old * patients who had savr, mini avr, or tavr exclusion criteria: * patients' refusal * suboptimal echocardiography data for rvef, rv size, rimp, rvfac, tapse, s', ste

Keywords: right ventricular dysfunction three-dimensional transesophageal echocardiography surgical aortic valve replacement mini-sternotomy aortic valve replacement transcatheter aortic valve replacement
attenuation of the side effect profile of regadenoson: study with aminophylline in patients with severe kidney disease undergoing myocardial perfusion imaging

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson

Summary: the routine administration of 75 mg of intravenous aminophylline in patients with severe chronic kidney disease undergoing a nuclear stress test with regadenoson (lexiscan®) can reduce or eliminate the incidence of diarrhea and other side effects related to regadenoson.

approximately 300 patients with severe chronic kidney disease who are referred for a nuclear stress testing of the heart with regadenoson (lexiscan®) will be recruited to participate in the study. following regadenoson (administered as part of a stress routine test protocol) participants will receive either aminophylline (75 mg - intravenously) or a matching inactive placebo (sterile salt water) injection. participants will be surveyed for gastrointestinal symptoms and other side effects related to regadenoson. the frequency and severity of such side effects will be compared between the two study groups (aminophylline vs. placebo).

Eligibility criteria:
inclusion criteria: * adult patients referred to undergo a clinically-indicated regadenoson-stress myocardial perfusion imaging at rush university medical center * stage iv or v chronic kidney disease (gfr \< 30, hemodialysis, and/or peritoneal dialysis). exclusion criteria: * patient refusal to participate * known allergic reaction to aminophylline. * pre-existing headache or acute/subacute gi illness with symptoms of diarrhea, abdominal discomfort, nausea or vomiting. * any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and acute coronary symptoms. * uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12 months or any seizure in the past week. * pregnant or breast-feeding women. * patients receiving anti-platelet agent dipyridamole (persantine® or aggrenox®).

Keywords: regadenoson chronic kidney disease renal failure lexiscan aminophylline spect myocardial perfusion imaging pharmacologic stress test patients with stage iv or v chronic kidney disease being assessed with nuclear stress testing of the heart using the stress agent regadenoson (lexiscan ®)
almond intervention in type 2 diabetes mellitus

Conditions: Cardiovascular Diseases

Summary: this prospective cohort study of an almond-enriched diet (within the overall context of asian indian dietary guidelines) was conducted to test the hypothesis that in patients with t2dm almond-enriched balanced diet improves glycemic measures and cvd risk factors.


Eligibility criteria:
inclusion criteria: * patients in the age range of 25-65 years * on stable doses of metformin from past 3 months * having hba1c less than 9% * ldl-c ≥100 mg/dl were recruited exclusion criteria: * patients on insulin therapy, plioglitazone, insulin secretagogues, beta blockers or steroids or suffering from diabetes for more than 10 years * having high uric acid levels (≥ 8 mg/dl), * with accelerated hypertension (stage 2 hypertension according to jnc guidelines) , hypothyroidism, suffering from acute infection or any debilitating disease or with renal failure, * appreciable weight loss (more than 10%) during past 6 months * patients with known food allergy, lipid altering medication or extraneous factors that can affect glycemic or lipid parameters
comparison of the effect of capsular bend on the rotational stability between two toric intraocular lenses

Conditions: Cataract

Summary: (1) to compare the difference of rotational stability and cbi between acrysof iq(sn6at) and tecnis(zcu) after cataract surgery. (2) to evaluate the influence of capsular bending on the rotational stability of these two kinds of intraocular lenses.

to compare the difference of rotational stability and cbi between acrysof iq(sn6at) and tecnis (zcu) torus intraocular lenses implanted after cataract surgery, and analyze the influence of capsular bag bending on the rotational stability of two kinds of astigmatism correction intraocular lenses after cataract surgery.

Eligibility criteria:
inclusion criteria:1.the patient's age is over 18 years old. 2.diagnosed as age-related cataract corneal astigmatism measured before operation is \> 0.75 d or predicted after operation after taking into account surgical astigmatism (sia). 3.pupil diameter \> 7 mm after mydriasis. 4.the astigmatism meridian between iolmaster and pentacam is the same (the meridian difference between the two instruments is within 15). 5.after operation, the anterior capsule completely covered the edge of intraocular lens optical surface. 6.able to understand, cooperate and complete all follow-up. - exclusion criteria: 1. moderate and severe dry eye 2. there is irregular corneal astigmatism. 3. combined with other ophthalmic diseases previous history of ophthalmic surgery. 4. the capsulorhexis is too large or eccentric, which can not cover the optical zone of intraocular lens all around, and there are intraoperative or postoperative complications. -
effect of metformin on disease progression in patients with cryptogenic cirrhosis (nash-related cirrhosis) with diabetes or impaired glucose tolerance or insulin resistance

Conditions: NASH Related Cirrhosis

Summary: in this study, consecutive patients with cryptogenic cirrhosis (nash-related cirrhosis), coming to ilbs (institute of liver \& biliary sciences) opd (out patient department) or getting admitted in the ward will be enrolled on fulfillment of inclusion/exclusion criteria and consent of the patient. these patients will be randomised to either metformin arm or conventional treatment arm. after enrollment these subjects will be monitored every three monthly for total of 12 months or till the primary endpoint is achieved. at the end of the study, outcome will be measured appropriately.


Eligibility criteria:
inclusion criteria: 1. age 18 years and above 2. patients with cryptogenic cirrhosis {nash (nash alcoholic steatohepatitis)-related cirrhosis} 3. presence of diabetes mellitus or insulin resistance exclusion criteria: 1. patients with heart failure 2. patients with acute kidney injury at the time of enrollment 3. patients with ckd (chronic kidney disease) or with s. creatinine \> 1 mg/dl 4. patient with active upper gi bleeding- not settled 5. patient with sirs/sepsis/shock 6. patient in icu (intensive care unit) 7. pregnancy 8. patients with hepatocellular carcinoma 9. patients who are not willing to participate in the study 10. patients with any form of decompensation at the time of enrollment in the study 11. patient with large esophageal varices/ patients who are on beta blocker other than those patients with hvpg (hepatic venous pressure gradient) non responder to betablocker 12. patient who has already been receiving metformin prior to enrollment in the study
examination how the administration period of teriparatide affects bone metabolism and bone mineral density prior to denosumab therapy

Conditions: Osteoporosis

Summary: the aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients: 1. the administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months. 2. the administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months. 3. the administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.


Eligibility criteria:
inclusion criteria: * osteoporotic patients who want to take teriparatide and denosumab exclusion criteria: * patients who are allergic to teriparatide or denosumab patients who are pregnant or breast-feedin
the effects of music therapy and aromatherapy interventions on pulse rate, blood pressure, anxiety, and self-esteem

Conditions: Aromatherapy; Music Therapy

Summary: appropriate intervention methods should be investigated to reduce stress and fatigue of students in psychomotor skills. the aim of this study is to reveal the effects of music therapy and aromatherapy interventions on pulse, blood pressure, anxiety and self-esteem levels of nursing students during injection application to the ventrogluteal region on a mannequin. hypotheses: h1a= during the ventrogluteal injection application of nursing students on a mannequin, aromatherapy and music therapy and aromatherapy application have an effect on pulse rate. h1b= during the ventrogluteal injection application of nursing students on a mannequin, aromatherapy and music therapy and aromatherapy application have an effect on blood pressure level. h1c= during the ventrogluteal injection application of nursing students on a mannequin, aromatherapy and music therapy and aromatherapy application have an effect on anxiety level. h1d= during the ventrogluteal injection application of nursing students on a mannequin, aromatherapy and music therapy and aromatherapy application have an effect on self-esteem level.

appropriate intervention methods should be investigated to reduce stress and relieve fatigue of students in psychomotor skills. the aim of this study is to reveal the effects of music therapy and aromatherapy interventions on pulse, blood pressure, fatigue and self-esteem levels of nursing students during ventrogluteal injection application. for this purpose, the investigators tried to provide more information to the literature for music therapy and aromatherapy interventions in this single-blind randomized controlled study.

Eligibility criteria:
inclusion criteria: * students who are first year students, and * volunteer to participate in the research will be included. exclusion criteria: * volunteer to participate in the research will not be included.

Keywords: pulse rate blood pressure anxiety self-esteem